DelveInsight's "Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Growth Hormone Deficiency, historical and forecasted epidemiology as well as the Growth Hormone Deficiency market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

1. Growth Hormone Deficiency Market
Growth Hormone Deficiency Market: Industry Analysis, Drugs, Key Companies by DelveInsight |
Ascendis Pharma, Pfizer, Opko, Lumos Pharma, Novo Nordisk, Ipsen, Pfizer and Others.
Growth hormone deficiency is a condition where the pituitary gland is unable to make enough
growth hormone. It can be caused by damage to the pituitary gland or another gland called the
hypothalamus. The injury can occur before birth (congenital), or during or after birth (acquired). A
third category has no known or diagnosable cause (idiopathic). Growth hormone deficiency may be
caused by a tumor in the brain. These tumors are normally located at the site of the pituitary gland
or the nearby hypothalamus region of the brain. In children and adults, serious head injuries,
infections, and radiation treatments can also cause Growth hormone deficiency, which is known as
acquired Growth hormone deficiency (AGHD). However, in rare cases, Growth hormone deficiency
can be part of a genetic syndrome such as Turner syndrome and Prader-Willi syndrome. Additionally,
in many cases, the cause of Growth hormone deficiency is not known or idiopathic.
DelveInsight's "Growth Hormone Deficiency Market Insights, Epidemiology, and Market Forecast-
2030" report delivers an in-depth understanding of the Growth Hormone Deficiency, historical and
forecasted epidemiology as well as the Growth Hormone Deficiency market trends in the United
States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of Growth hormone deficiency Market Report Facts are:
 As per the study by Bonfig et al. (2019) titled “Mini Review/Commentary: Growth Hormone
Treatment in Children with Type 1 Diabetes,” the prevalence of GHD ranges between 1/3500
and 1/8700 in Germany.
 According to the Boston Children’s Hospital, about 1 in 4,000–10,000 children have GHD.
 Several secondary sources suggest that GHD is slightly more prevalent in males than in
females.
 According to the Growth Hormone Foundation estimates, more than 50,000 adults in the
United States are growth hormone deficient, and 6,000 new cases are reported each year,
including GHD children who transition to GHD as an adult.
 It is estimated that in the adult UK population at any given time, approximately 1 in every
10,000 people will have adult-onset GHD, which works out to approximately 12,600 adults
with GHD in England and Wales.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-
hormone-deficiency-ghd-market
Some of Growth hormone deficiency Companies are:
 Ascendis Pharma
 Pfizer
 Opko

2.  Lumos Pharma
 Novo Nordisk
 Ipsen
 Pfizer
 And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-
hormone-deficiency-ghd-market
Scope of the Growth hormone deficiency Report:
 The report covers the descriptive overview of Growth Hormone Deficiency, explaining its
causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
 Comprehensive insight has been provided into the Growth Hormone Deficiency
epidemiology and treatment in the 7MM
 Additionally, an all-inclusive account of both the current and emerging therapies for Growth
Hormone Deficiency are provided, along with the assessment of new therapies, which will
have an impact on the current treatment landscape
 A detailed review of Growth Hormone Deficiency market; historical and forecasted is
included in the report, covering drug outreach in the 7MM
 The report provides an edge while developing business strategies, by understanding trends
shaping and driving the global Growth Hormone Deficiency market
Some of Growth hormone deficiency therapies are:
 TransCon hGH
 Somatrogon
 LUM-201
 Norditropin
 Sogroya (somapacitan)
 Increlex
 Genotropin
 And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-
hormone-deficiency-ghd-market
Table of Contents:
1. Key Insights
2. Executive Summary of Growth Hormone Deficiency
3. Competitive Intelligence Analysis for Growth Hormone Deficiency
4. Growth Hormone Deficiency: Market Overview at a Glance
5. Growth Hormone Deficiency: Disease Background and Overview
6. Patient Journey

3. 7. Growth Hormone Deficiency Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Growth Hormone Deficiency Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Growth Hormone Deficiency: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Growth Hormone Deficiency
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Request for Detailed TOC: https://www.delveinsight.com/sample-request/growth-hormone-
deficiency-ghd-market
Other Links:
 Electrophysiology Devices Market
 Growth Hormone Deficiency Market
 Interventional Neuroradiology Market
 Intracranial Pressure Monitoring Devices Market
 Foot and Ankle Devices Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life
sciences. It supports pharma companies by providing end-to-end comprehensive solutions to
improve their performance.
Contact us
Ankit Nigam
info@delveinsight.com
+91-9650213330

4. https://www.delveinsight.com/
Connect With Us at:
LinkedIn | Facebook | Twitter
Request for Free Sample Report: https://www.delveinsight.com/sample-request/growth-
hormone-deficiency-ghd-market